Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

March 1, 2022 updated by: Yongchang Zhang, Hunan Province Tumor Hospital

This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.

Study Overview

Status

Completed

Conditions

Non-squamous NSCLC

Detailed Description

This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.

Study Type

Observational

Enrollment (Actual)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

China
- Hunan
  - Changsha, Hunan, China, 410013
    - Hunan Cancer Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Advanced Metastatic Non-squamous Non-small Cell Lung Cancer

Description

Inclusion Criteria:

18，Advanced Metastatic Non-squamous NSCLC Treatment Plan is atezolizumab-bevacizumab-carboplatin-paclitaxel

Exclusion Criteria:

Patients with contraindication of chemotherapy Pregnant or breast feeding women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
OS Time Frame: September 2019- september 2021	overall survival	September 2019- september 2021
PFS Time Frame: September 2019- september 2021	progression-free survival	September 2019- september 2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hunan Province Tumor Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2019

Primary Completion (Actual)

May 1, 2021

Study Completion (Actual)

September 15, 2021

Study Registration Dates

First Submitted

January 22, 2022

First Submitted That Met QC Criteria

March 1, 2022

First Posted (Actual)

March 2, 2022

Study Record Updates

Last Update Posted (Actual)